Blood & Cancer
FDA approves combo immunotherapy for mesothelioma, atezolizumab strikes out in ovarian cancer, and more
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:30
- Mas informaciones
Informações:
Sinopsis
Hematology-Oncology News: Radiotherapy planning scans reveal breast cancer patients’ CVD risk (https://bit.ly/2FeoJiH) FDA OKs combination immunotherapy for first-line mesothelioma treatment (https://bit.ly/2Ff77mS) Apatinib plus gefitinib: Better PFS but more toxicity (https://bit.ly/34IyVsn) Atezolizumab strikes out in ovarian cancer (https://bit.ly/3iPjXG1) Email Blood & Cancer at podcasts@mdedge.com and learn more at https://www.mdedge.com/podcasts/blood-cancer
